{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:08:27Z","timestamp":1790086107457,"version":"4.0.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Nordic Cancer Union"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Cervical cytology has been the primary method of cervical cancer screening for decades. Tests that detect viral HPV are shown in several randomized trials to provide better protection against cancer compared with cytology. HPV-based screening has been implemented alongside cytology in the Nordic countries for several years. The aim of this study was to compare cytology and HPV-based screening in the colposcopy referrals and detection rates of cervical lesions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Individual-level screening data from Finland, Iceland, Norway and Sweden were harmonized and aggregated locally. We utilized data for tests taken during years 2015\u201317 and biopsies taken during years 2015\u201319 to allow 24\u2009months of follow-up. Age-standardized estimates and age-adjusted risk ratios for six different outcomes of screening management were calculated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The age-standardized colposcopy rates were higher in HPV-based testing compared with cytology in Finland (3.5% vs. 0.9%) and Norway (6.0% vs. 4.1%) but lower in Sweden (3.7% vs. 4.9%). The relative detection rate of cervical intraepithelial neoplasia grade 2 and above in HPV-based testing compared with cytology was highest in Finland (RR 2.37, 95% CI 2.13\u20132.63) and Norway (RR 1.66, 95% CI 1.57\u20131.72) while in Sweden the difference was not statistically significant (RR 0.98, 95% CI 0.95\u20131.00).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The effects of implementing HPV screening varied by country as different screening algorithms were implemented. HPV-based screening increases colposcopy rates mainly through referrals from increased repeat testing and detection rate is therefore significantly higher compared with cytology. Monitoring of these indicators in subsequent rounds of HPV-based screening remains essential.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurpub\/ckad225","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T16:52:36Z","timestamp":1706028756000},"page":"354-360","source":"Crossref","is-referenced-by-count":11,"title":["Divergent effects of switching from cytology to HPV-based screening in the Nordic countries"],"prefix":"10.1093","volume":"34","author":[{"given":"Veli-Matti","family":"Partanen","sequence":"first","affiliation":[{"name":"Finnish Cancer Registry , Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joakim","family":"Dillner","sequence":"additional","affiliation":[{"name":"Department of Clinical Science, Intervention and Technology - CLINTEC, Karolinska Institutet , Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameli","family":"Trop\u00e9","sequence":"additional","affiliation":[{"name":"Section for Cervical Cancer Screening, Cancer Registry of Norway , Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1g\u00fast Ingi","family":"\u00c1g\u00fastsson","sequence":"additional","affiliation":[{"name":"Icelandic Cancer Screening Coordination Center , Reykjav\u00edk, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"L\u00f6nnberg","sequence":"additional","affiliation":[{"name":"Finnish Cancer Registry , Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirpa","family":"Hein\u00e4vaara","sequence":"additional","affiliation":[{"name":"Finnish Cancer Registry , Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahti","family":"Anttila","sequence":"additional","affiliation":[{"name":"Finnish Cancer Registry , Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,22]]},"reference":[{"key":"2024040320150911400_ckad225-B1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2024040320150911400_ckad225-B2","volume-title":"Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem","author":"World Health Organization (WHO)","year":"2020"},{"key":"2024040320150911400_ckad225-B3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/(SICI)1097-0215(19990924)83:1<59::AID-IJC12>3.0.CO;2-N","article-title":"Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963\u20131995: recent increase in cervical cancer incidence","volume":"83","author":"Anttila","year":"1999","journal-title":"Int J Cancer"},{"key":"2024040320150911400_ckad225-B4","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1080\/00016340500324423","article-title":"Cervical cancer incidence in Denmark over six decades (1943-2002)","volume":"85","author":"Kyndi","year":"2006","journal-title":"Acta Obstet Gynecol Scand"},{"key":"2024040320150911400_ckad225-B5","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/ijc.29541","article-title":"Cervical cancer prevented by screening: long-term incidence trends by morphology in Norway","volume":"137","author":"L\u00f6nnberg","year":"2015","journal-title":"Int J Cancer"},{"key":"2024040320150911400_ckad225-B6","author":"Lar\u00f8nningen"},{"key":"2024040320150911400_ckad225-B7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ejca.2019.12.013","article-title":"Effect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic review","volume":"127","author":"Jansen","year":"2020","journal-title":"Eur J Cancer"},{"key":"2024040320150911400_ckad225-B8","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1177\/0969141321992404","article-title":"Comparison of cytology and human papillomavirus-based primary testing in cervical screening programs in the Nordic countries","volume":"28","author":"Partanen","year":"2021","journal-title":"J Med Screen"},{"key":"2024040320150911400_ckad225-B9","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV vaccination and the risk of invasive cervical cancer","volume":"383","author":"Lei","year":"2020","journal-title":"N Engl J Med"},{"key":"2024040320150911400_ckad225-B10","first-page":"1","article-title":"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study","volume":"8","author":"Falcaro","year":"2021","journal-title":"Lancet"},{"key":"2024040320150911400_ckad225-B11","author":"European Commission","year":"2021"},{"key":"2024040320150911400_ckad225-B12","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","article-title":"Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials","volume":"383","author":"Ronco","year":"2014","journal-title":"Lancet"},{"key":"2024040320150911400_ckad225-B13","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1080\/0284186X.2020.1821089","article-title":"Adherence to international recommendations in the governance and organisation of Nordic cervical cancer screening programmes","volume":"59","author":"Partanen","year":"2020","journal-title":"Acta Oncol"},{"key":"2024040320150911400_ckad225-B14","doi-asserted-by":"crossref","first-page":"c1804","DOI":"10.1136\/bmj.c1804","article-title":"Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme","volume":"340","author":"Anttila","year":"2010","journal-title":"BMJ"},{"key":"2024040320150911400_ckad225-B15","author":"Finnish Cancer Registry","year":"2021"},{"key":"2024040320150911400_ckad225-B16","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1080\/0284186X.2019.1615637","article-title":"NordScreen\u2014an interactive tool for presenting cervical cancer screening indicators in the Nordic countries","volume":"58","author":"Partanen","year":"2019","journal-title":"Acta Oncol"},{"key":"2024040320150911400_ckad225-B17","volume-title":"European Guidelines for Quality Assurance in Cervical Cancer Screening","author":"Arbyn","year":"2008","edition":"2nd edn"},{"key":"2024040320150911400_ckad225-B18","volume-title":"European Guidelines for Quality Assurance in Cervical Cancer Screening\u2014Second Edition Supplements","author":"Anttila","year":"2015"},{"key":"2024040320150911400_ckad225-B19","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/cyt.12652","article-title":"Implementation of HPV-based cervical cancer screening in an organised regional screening programme: 3 years of experience","volume":"30","author":"Veijalainen","year":"2019","journal-title":"Cytopathology"},{"key":"2024040320150911400_ckad225-B20","doi-asserted-by":"crossref","first-page":"l240","DOI":"10.1136\/bmj.l240","article-title":"Primary cervical screening with high risk human papillomavirus testing: observational study","volume":"364","author":"Rebolj","year":"2019","journal-title":"BMJ"},{"key":"2024040320150911400_ckad225-B21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/CLEP.S243546","article-title":"Clinical performance of human papillomavirus (HPV) testing versus cytology for cervical cancer screening: Results of a large Danish implementation study","volume":"12","author":"Thomsen","year":"2020","journal-title":"Clin Epidemiol"},{"key":"2024040320150911400_ckad225-B22","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12913-016-1375-9","article-title":"Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use","volume":"16","author":"Smith","year":"2016","journal-title":"BMC Health Serv Res"},{"key":"2024040320150911400_ckad225-B23","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.cmi.2019.09.006","article-title":"Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans","volume":"26","author":"Maver","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2024040320150911400_ckad225-B24","doi-asserted-by":"crossref","first-page":"e7789","DOI":"10.1136\/bmj.e7789","article-title":"Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland","volume":"345","author":"Leinonen","year":"2012","journal-title":"BMJ"},{"key":"2024040320150911400_ckad225-B25","doi-asserted-by":"crossref","first-page":"e1003748","DOI":"10.1371\/journal.pmed.1003748","article-title":"Organized primary human papillomavirus- based cervical screening: a randomized healthcare policy trial","volume":"18","author":"Elfstr\u00f6m","year":"2021","journal-title":"PLoS Med"},{"key":"2024040320150911400_ckad225-B26","doi-asserted-by":"crossref","first-page":"106219","DOI":"10.1016\/j.ypmed.2020.106219","article-title":"Differences in cervical test coverage by age, socioeconomic status, ethnic origin and municipality type\u2014a nationwide register-based study","volume":"139","author":"Pankakoski","year":"2020","journal-title":"Prev Med"},{"key":"2024040320150911400_ckad225-B27","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12916-019-1460-0","article-title":"Introduction of primary screening using high-risk HPV DNA detection in the Dutch cervical cancer screening programme: a population-based cohort study","volume":"17","author":"Aitken","year":"2019","journal-title":"BMC Med"},{"key":"2024040320150911400_ckad225-B28","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ygyno.2014.11.076","article-title":"Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test","volume":"136","author":"Wright","year":"2015","journal-title":"Gynecol Oncol"},{"key":"2024040320150911400_ckad225-B29","doi-asserted-by":"crossref","first-page":"k499","DOI":"10.1136\/bmj.k499","article-title":"Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis","volume":"360","author":"Tainio","year":"2018","journal-title":"BMJ"},{"key":"2024040320150911400_ckad225-B30","doi-asserted-by":"crossref","first-page":"i3633","DOI":"10.1136\/bmj.i3633","article-title":"Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis","volume":"354","author":"Kyrgiou","year":"2016","journal-title":"BMJ"},{"key":"2024040320150911400_ckad225-B31","volume-title":"WHO Classification of Tumours of Female Reproductive Organs","author":"Kurman","year":"2014","edition":"4th edn"},{"key":"2024040320150911400_ckad225-B32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/LGT.0000000000000494","article-title":"Clinical utility of human papillomavirus genotyping in cervical cancer screening: a systematic review","volume":"24","author":"Bonde","year":"2020","journal-title":"J Low Genit Tract Dis"},{"key":"2024040320150911400_ckad225-B33","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/ijc.33519","article-title":"Human papillomavirus load and genotype analysis improves the prediction of invasive cervical cancer","volume":"149","author":"Hortlund","year":"2021","journal-title":"Int J Cancer"},{"key":"2024040320150911400_ckad225-B34","author":"European Commission","year":"2019"}],"container-title":["European Journal of Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurpub\/article-pdf\/34\/2\/354\/57148763\/ckad225.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurpub\/article-pdf\/34\/2\/354\/57148763\/ckad225.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T20:15:48Z","timestamp":1712175348000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurpub\/article\/34\/2\/354\/7585424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,1,22]]},"published-print":{"date-parts":[[2024,4,3]]}},"URL":"https:\/\/doi.org\/10.1093\/eurpub\/ckad225","relation":{},"ISSN":["1101-1262","1464-360X"],"issn-type":[{"value":"1101-1262","type":"print"},{"value":"1464-360X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4,1]]},"published":{"date-parts":[[2024,1,22]]}}}